MARKET

AKTS

AKTS

AKTIS ONCOLOGY INC
NASDAQ
29.44
-1.71
-5.49%
After Hours: 30.06 +0.62 +2.11% 16:24 06/26 EDT
OPEN
31.06
PREV CLOSE
31.15
HIGH
32.88
LOW
28.45
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
33.53
52 WEEK LOW
14.72
MARKET CAP
1.63B
P/E (TTM)
-43.5696
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKTS last week (0615-0619)?
Weekly Report · 5d ago
Aktis is a Strong Buy at Raymond James on therapeutic platform
Seeking Alpha · 06/16 16:28
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
Benzinga · 06/16 11:15
Aktis Oncology Price Target Announced at $40.00/Share by Raymond James
Dow Jones · 06/16 10:05
Aktis Oncology Initiated at Strong Buy by Raymond James
Dow Jones · 06/16 10:05
Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40
Benzinga · 06/16 09:55
U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation
Reuters · 06/16 08:11
Aktis Oncology initiated with a Strong Buy at Raymond James
TipRanks · 06/15 20:12
More
About AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.

Webull offers Aktis Oncology, Inc. stock information, including NASDAQ: AKTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTS stock methods without spending real money on the virtual paper trading platform.